SRNE - Sorrento Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.8400
-0.0500 (-1.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close3.8900
Open3.9000
Bid3.7000 x 1800
Ask3.8600 x 3000
Day's Range3.7700 - 3.9700
52 Week Range1.8000 - 8.2500
Volume937,129
Avg. Volume2,953,648
Market Cap440.494M
Beta (3Y Monthly)2.97
PE Ratio (TTM)N/A
EPS (TTM)-1.9200
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.67
Trade prices are not sourced from all markets
  • ACCESSWIREyesterday

    Cannabis Bargains After Aphria's News Started Sell-Off-THC Therapeutics, Inc.

    HENDERSON, NV / ACCESSWIRE / April 18, 2019 / Cannabis stocks were a sea of red on Monday, weighed down by Aphria Inc. after it swung to a wide loss in the third quarter that outweighed a surge in revenue. ...

  • GlobeNewswire5 days ago

    Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin (RTX) for multiple life-threatening cardiovascular disorders, including IND enabling toxicology and proof-of-principle animal studies. RTX has potential clinical benefits derived from its ability to modulate neurogenic inflammation and afferent nerve signaling commonly associated with chronic degenerative conditions.

  • Why Sorrento Therapeutics Is Jumping Today
    Motley Fool9 days ago

    Why Sorrento Therapeutics Is Jumping Today

    Good news from a preclinical study is exciting investors about the potential for one of Sorrento's experimental drugs.

  • GlobeNewswire9 days ago

    Sorrento Therapeutics Announces Discovery of a Potential Non-Dopaminergic Approach to Controlling Parkinson’s Motor Symptoms With Resiniferatoxin (RTX) Intrathecal Administration

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announces positive and better than initially hoped for top line results in a discovery study aimed at exploring potential benefits of resiniferatoxin in controlling neuro-inflammatory processes associated with Parkinson’s disease in a rodent model. Parkinson’s disease (PD) is a chronic neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rest tremor, postural disturbances, and rigidity. Transient receptor potential vanilloid 1 (TRPV1) is involved in pain perception and is highly expressed in sensory neurons.

  • Here's Why Sorrento Therapeutics Soared 134% in March
    Motley Fool10 days ago

    Here's Why Sorrento Therapeutics Soared 134% in March

    The early-stage biotech jumped without any significant news.

  • Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme
    American City Business Journals15 days ago

    Sorrento Therapeutics sues Soon-Shiong over alleged cancer drug scheme

    Biopharmaceutical company Sorrento Therapeutics Inc. has filed lawsuits against Dr. Patrick Soon-Shiong and his NantWorks network of companies, accusing the biotech entrepreneur of engaging in a “catch and kill” plan that ultimately blocked the release of Sorrento’s new cancer drug.

  • Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?
    Zacks15 days ago

    Are Options Traders Betting on a Big Move in Sorrento Therapeutics (SRNE) Stock?

    Investors need to pay close attention to Sorrento Therapeutics (SRNE) stock based on the movements in the options market lately.

  • GlobeNewswire24 days ago

    Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

    Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects with Lumbosacral Radiculopathy, a.k.a. All subjects experienced rapid reduction of leg and back pain following two SP-102 injection treatments, with group median for average pain in affected leg reduced over 50% throughout 28 days for each injection (100% response rate). Scilex expects SP-102 to be the first FDA approved non-opioid epidural injections for sciatica with the potential to replace the current 10 to 11 million off-label epidural steroid injections administered each year in the U.S.

  • Analysts Give Favorable Opinions on Sorrento Therapeutics
    Market Realist28 days ago

    Analysts Give Favorable Opinions on Sorrento Therapeutics

    How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 295.22% for Sorrento Therapeutics (SRNE) based on the stock’s

  • Sorrento Therapeutics News: Why SRNE Stock Is On The Move
    InvestorPlace28 days ago

    Sorrento Therapeutics News: Why SRNE Stock Is On The Move

    Recent Sorrento Therapeutics news has SRNE stock on a roller coaster ride today.Source: Shutterstock Sorrento Therapeutics (NASDAQ:SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals is merging with Semnur Pharmaceuticals. This merger has the two companies coming together in an effort to create a leader in the non-opioid pain medicine market. The new company's name is Scilex Holding CompanyThe Sorrento Therapeutics news means that the company's stake in Scilex Pharmaceuticals is being converted into a new stake at the combined company. This has its 77% stake in Scilex Pharmaceuticals becoming a 58% stake in Scilex Holding Company.InvestorPlace - Stock Market News, Stock Advice & Trading Tips"This transaction is highly synergistic," Dr. Henry Ji, Chairman and CEO of Sorrento Therapeutics, said in a statement. "Scilex has built up a commercial organization with over 100 highly experienced sales representatives, fully staffed marketing, market access, and medical liaison teams while Semnur has a very exciting Phase 3 compound in non-opioid pain management."Scilex Pharmaceuticals' ZTlido is already performing well in the early months of its commercial release. Semnur also has a compound that is in a Phase 3 trial and could also be a strong win for the newly-merged company. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Sorrento Therapeutics news today has SRNE stock on a wild ride. It started off up up 8% on Friday morning and reached a peak increase of 24% during morning trading. However, the stock is now down 9% as of Friday afternoon. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks That Will Continue to Rebound in 2019 * 5 Stocks To Buy for the Happiest Employees * 7 ETFs for a Millennial Portfolio As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Sorrento Therapeutics News: Why SRNE Stock Is On The Move appeared first on InvestorPlace.

  • GlobeNewswire28 days ago

    Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

    Sorrento Therapeutics, Inc. (SRNE) announced today that its majority owned subsidiary Scilex Pharmaceuticals Inc. (Scilex) has closed a transaction to merge with Mountain View, California, based Semnur Pharmaceuticals, Inc. (Semnur) to form a new company, Scilex Holding Company (Scilex Holding). Sorrento’s equity stake in Scilex (77%) has been converted into a 58% stake in Scilex Holding. With Scilex’s lead product ZTlido® (lidocaine topical system 1.8%) ramping rapidly in the early months of commercial launch and Semnur’s lead compound (non-opioid corticosteroid gel) in Phase 3 pivotal studies for the treatment of lumbar radicular pain/sciatica with Fast Track status from the FDA, Scilex Holding is well positioned to become a global leader in non-opioid pain management.

  • GlobeNewswirelast month

    Yuhan Corp and Sorrento Therapeutics Announce Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

    Yuhan) and Sorrento Therapeutics, Inc. (SRNE) announced today that ImmuneOncia, a joint venture formed in September 2016, has completed the Phase 1 study of IMC-001 (also known as STI-3031), a fully human anti-PD-L1 monoclonal antibody (mAb) immune checkpoint inhibitor. The mAb blocks the interaction of PD-L1 protein with its receptor PD-1, suppressing the inhibitory signal to T cells and enhancing the killing effect of T cells on tumors.

  • GlobeNewswire2 months ago

    Sorrento Therapeutics to Present Corporate Update at Two Investor Conferences

    SAN DIEGO, Feb. 25, 2019 -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that senior management will provide a corporate overview at the upcoming.

  • GlobeNewswire2 months ago

    Yuhan Corp and Sorrento Therapeutics Announce Closing of a $40m USD Financing for Joint Venture ImmuneOncia to Support Advancement of Immuno-Oncology Program

    The proceeds of the transaction will be utilized to advance ImmuneOncia’s Phase I and II clinical studies of IMC-001, a PD-L1 monoclonal antibody, as well as to support its earlier stage programs. As a result of this financing, ImmuneOncia is expected to be sufficiently funded in preparation for an initial public offering, which is expected to occur in 2021.

  • What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?
    Simply Wall St.2 months ago

    What Kind Of Shareholders Own Sorrento Therapeutics, Inc. (NASDAQ:SRNE)?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Sorrento Therapeutics,Read More...

  • GlobeNewswire3 months ago

    New Research: Key Drivers of Growth for Tapestry, FIS, News Corporation, Ollie's Bargain Outlet, Covanta Holding, and Sorrento Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

    NEW YORK, Jan. 31, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE3 months ago

    Health Stocks Benefitting the Most from Rally

    HENDERSON, NV / ACCESSWIRE / January 22, 2019 / The stock market reached a level toward the end of last year where investors and analysts feared a recession. Some of this fear was over a U.S. China trade ...

  • GlobeNewswire3 months ago

    Sorrento Therapeutics Announces Interim Results In Osteoarthritis Knee Pain Phase 1b Trial of Resiniferatoxin With Positive Therapeutic Signal and Absence of Dose Limiting Toxicities; Pivotal Trials Targeted to Start Later 2019

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced that the phase 1b study of its non-opioid, afferent nerve ablating drug candidate (resiniferatoxin or “RTX”) for the treatment of pain from osteoarthritis in the knee (intra-articular route of administration) interim data analysis of over 30 patients had positive activity, prompting Sorrento to start planning pivotal studies to start in 2019. Rapid onset of pain relief (day following injection) and sustained clinical benefits (84 days) at the lowest dose tested. The “Phase 1b double-blind study to assess the safety and preliminary efficacy of intra-articular administration of resiniferatoxin versus placebo for the treatment of pain due to moderate to severe osteoarthritis of the knee” was expected to recruit about 40 patients in 5 dose level cohorts or until a maximum tolerated dose (MTD) was reached.

  • GlobeNewswire3 months ago

    Scilex Announces Addition of ZTlido® to Express Scripts National Formularies

    Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that Express Scripts has added ZTlido® (lidocaine topical system) 1.8% to its commercial national formularies representing nearly 30 million lives.  ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX worked diligently with Express Scripts to ensure that patients and providers will have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. “Express Scripts’ decision to include ZTLIDO on its national formularies in recognition of the benefit it can provide to patients with post-herpetic neuralgia, or PHN, is an important milestone for SCILEX.

  • GlobeNewswire3 months ago

    Scilex Announces ZTlido® Insurance Coverage for ~100 Million Insured Lives(1)

    Scilex Pharmaceuticals Inc. (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (SRNE), today announced that ZTlido® (lidocaine topical system) 1.8% (ZTLIDO) is covered by nearly 100M U.S. insured lives1.  ZTLIDO is indicated for relief of pain associated with postherpetic neuralgia (PHN), also referred to as post-shingles pain. “SCILEX has been working closely with pharmacy benefit managers (PBMs) and health plans to help ensure patients and providers have access to ZTLIDO, a non-opioid, non-abusive treatment option for post-herpetic neuralgia,” said Mike Sweeting, Vice President, Market Access, Scilex. ZTLIDO is a topical system product that uses an advanced adhesion technology, providing more efficient lidocaine delivery than Lidoderm® (lidocaine patch 5%)* over a full 12 hours.

  • GlobeNewswire3 months ago

    Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference

    Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO conference in San Francisco on January 5th, 2019 at 2:00PM PST at the Four Seasons Hotel San Francisco (prior to the JPM Healthcare Conference). The panel will discuss “Adventures in Financing: Raising Capital in 2018”, with a focus on alternative financing and how innovative biotechnology companies can leverage the value of their assets in commercial and/or development stage to seek significant non-dilutive funding.

  • GlobeNewswire5 months ago

    Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million

    Sorrento Therapeutics, Inc. (SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150 million. The financing is being provided by funds and accounts managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm.

  • GlobeNewswire5 months ago

    Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

    Sorrento Therapeutics, Inc. (SRNE) ("Sorrento") announced today the release of data from a phase 1b clinical trial administering anti-CEA CAR-T by utilizing a unique Pressure-Enabled Drug Delivery (PEDD) manufactured by TriSalus™ Life Sciences. The preliminary data for the Hepatic Immunotherapy for Metastases (HITM-SURE) clinical trial results will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held November 7-11 in Washington, DC. Five patients, four pancreatic and one colorectal, with carcinoembryonic antigen–positive (CEA+), unresectable stage IV adenocarcinoma with liver metastases, who had failed one or more lines of systemic chemotherapy, each received three hepatic artery infusions of Sorrento autologous anti-CEA CAR-T cells using the Hepatic Immunotherapy for Metastases (HITM) method.